Top

Published in:

01-02-2006

Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Hepatocellular Carcinoma

Authors: Kenya Yoshida, MD, Yasuhiko Tomita, MD, Yorihide Okuda, MD, Shinji Yamamoto, MD, Hirayuki Enomoto, MD, Hirokazu Uyama, MD, Hiroaki Ito, MD, Yoshihiko Hoshida, MD, Katsuyuki Aozasa, MD, Hiroaki Nagano, MD, Masato Sakon, MD, Ichiro Kawase, MD, Morito Monden, MD, Hideji Nakamura, MD

Published in: Annals of Surgical Oncology | Issue 2/2006

Abstract

Background

Hepatoma-derived growth factor (HDGF) is involved in hepatocarcinogenesis, as well as in liver development and regeneration. This study investigated the correlation of HDGF expression with differentiation and prognosis of hepatocellular carcinoma (HCC).

Methods

HDGF expression in 100 patients with HCC (81 men and 19 women) with ages ranging from 34 to 81 years (median, 61 years) receiving surgical treatment was analyzed by immunohistochemistry. HDGF messenger RNA expression was evaluated in 10 cases by reverse transcription-polymerase chain reaction. The immunostaining pattern in HCCs was categorized as a positive HDGF index (showing positive staining in >90% of tumor cells in both nucleus and cytoplasm) or a negative HDGF index (all others).

Results

Twenty-seven cases (27%) showed a positive and 73 (73%) showed a negative HDGF index. HDGF messenger RNA expression was significantly higher in four cases with a positive HDGF index than in six with a negative index. Cases with well-differentiated histological characteristics showed a higher rate of positive HDGF index than those with a poorly differentiated subtype. Univariate and multivariate analysis revealed significantly poorer disease-free and overall survivals in patients with a positive HDGF index compared with patients with a negative index.

Conclusions

These findings suggest the potential utility of HDGF immunohistochemistry in determining the prognosis of HCC.

Parkin DM, Muir CS. Cancer Incidence in Five Continents: Comparability and Quality of Data. Lyon: International Agency for Research on Cancer Scientific Publications, 1992; 45–173

Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790–9CrossRefPubMed

Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995;221:291–8PubMedCrossRef

Lau H, Fan ST, Ng IO, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998;83:2302–11CrossRefPubMed

Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63–70CrossRefPubMed

Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527–36CrossRefPubMed

Ng IO. Prognostic significance of pathological and biological factors in hepatocellular carcinoma. J Gastroenterol Hepatol 1998;13:666–70PubMedCrossRef

Nakamura H, Kambe H, Egawa T, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989;183:273–84CrossRefPubMed

Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 1994;269:25143–9PubMed

10.

Izumoto Y, Kuroda T, Harada H, Kishimoto T, Nakamura H. Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino terminus. Biochem Biophys Res Commun 1997;238:26–32CrossRefPubMed

11.

Kishima Y, Yamamoto H, Izumoto Y, et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 2002;277:10315–22CrossRefPubMed

12.

Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001;276:37564–8CrossRefPubMed

13.

Enomoto H, Yoshida K, Kishima Y, et al. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002;36:1519–27CrossRefPubMed

14.

Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 2000;105:567–75PubMedCrossRef

15.

Kishima Y, Yoshida K, Enomoto H, et al. Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepatogastroenterology 2002;49:1639–44PubMed

16.

Oliver JA, Al-Awqati Q. An endothelial growth factor involved in rat renal development. J Clin Invest 1998;102:1208–19PubMedCrossRef

17.

Okuda Y, Nakamura H, Yoshida K, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 2003;94:1034–41CrossRefPubMed

18.

Yoshida K, Nakamura H, Okuda Y, et al. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J Gastroenterol Hepatol 2003;18:1293–301PubMedCrossRef

19.

Edmondson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503PubMedCrossRef

20.

Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–5PubMedCrossRef

21.

Kaplan E, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–81CrossRef

22.

Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187–220

23.

The Liver Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994;74:2772–80CrossRef

24.

Fusenig NE, Breitkreutz D, Boukamp P, Tomakidi P, Stark HJ. Differentiation and tumor progression. Recent Results Cancer Res 1995;139:1–19PubMed

25.

Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172–8CrossRefPubMed

26.

Sugihara S, Nakashima O, Kojiro M, Majima Y, Tanaka M, Tanikawa K. The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer 1992;70:1488–92PubMedCrossRef

27.

Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688–96CrossRefPubMed

28.

Morimitsu Y, Hsia CC, Kojiro M, Tabor E. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 1995;26:1126–32CrossRefPubMed

29.

Nart D, Arikan C, Akyildiz M, et al. Hepatocellular carcinoma in liver transplant era: a clinicopathologic analysis. Transplant Proc 2003;35:2986–90CrossRefPubMed

Title: Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Hepatocellular Carcinoma
Authors: Kenya Yoshida, MD
Yasuhiko Tomita, MD
Yorihide Okuda, MD
Shinji Yamamoto, MD
Hirayuki Enomoto, MD
Hirokazu Uyama, MD
Hiroaki Ito, MD
Yoshihiko Hoshida, MD
Katsuyuki Aozasa, MD
Hiroaki Nagano, MD
Masato Sakon, MD
Ichiro Kawase, MD
Morito Monden, MD
Hideji Nakamura, MD
Publication date: 01-02-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.11.035

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Hepatocellular Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2006

HER-2/neu Expression in Primary Breast Cancer With Sentinel Lymph Node Metastasis

Induction Cisplatin and Paclitaxel Followed by Combination Chemoradiotherapy with 5-Fluorouracil, Cisplatin, and Paclitaxel Before Resection in Localized Esophageal Cancer: A Phase II Report

Expressing the Surgery First Position on Treatment of Synchronous Colorectal Metastases in the Asymptomatic Patient

Outcomes of Mass Screening for Gastric Carcinoma

The Influence of Biologic Factors on the Surgical Decision in Advanced Neuroblastoma

Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion